Foundayo Is Here. If You’re Succeeding on Zepbound, the Data Says Don’t Switch.
If you are losing weight on Eli Lilly’s Zepbound injections or any other form of GLP-1s, should you switch to the manufacturer’s new pill?
- The FDA has approved Foundayo (orforglipron), the first small-molecule oral GLP-1 from Eli Lilly which features fewer restrictions than the Wegovy pill.
- Trials showed Wegovy patients regained only 5% of their lost weight when they switched to Foundayo. Zepbound patients regained 20%. That is a 4x difference.
- Clinical takeaway: If you are succeeding on Zepbound injections, the data supports staying on them.
- Rivas prescribes Foundayo, Wegovy, Zepbound, and the full range of FDA-approved GLP-1s.
If you are losing weight on Eli Lilly’s Zepbound injections or any other form of GLP-1s, the question your friends are going to ask now is simple: Should you switch to the manufacturer’s new pill?
The data clearly says, “No.”
On April 1, 2026, the FDA approved Foundayo, Eli Lilly’s new once-daily GLP-1 pill. No needle. No refrigeration. No 30-minute wait before breakfast like with the Wegovy pill. On paper, it solves every complaint patients have ever had about injectable GLP-1s.
But Foundayo is not “Zepbound in a Pill.” It is a different molecule with a different mechanism and, according to a trial Lilly itself released in December 2025, different maintenance math. If you are already losing weight on Zepbound, switching may cause weight regain.
The Data Nobody Is Talking About
The headline study is called ATTAIN-MAINTAIN. It took patients who had already lost meaningful weight on Zepbound or Wegovy injections, then switched them to Foundayo for 52 weeks to see whether the pill could hold onto those results.
Here is what it found:
Patients who lost weight on Wegovy injections (average loss: 40.7 pounds) regained about 5% of that weight on the switch to Foundayo. Roughly 2 pounds over a year. Essentially a lateral move.
Patients who lost weight on Zepbound injections (average loss: 54.8 pounds) regained about 20% of that weight on the switch. Roughly 11 pounds over a year. Real, measurable, clinically meaningful regain.
Percent of lost weight regained after switching to Foundayo
ATTAIN-MAINTAIN Phase 3 trial. Eli Lilly, December 2025.
Source: ATTAIN-MAINTAIN topline data, Eli Lilly, December 18, 2025.
That is a 4x difference in proportional regain between the two cohorts. It is the single most important finding in GLP-1 medicine this year, and almost no one outside of obesity clinics is talking about it.
Dr. Beverly Tchang, a practicing obesity specialist writing in Medscape, read the data the same way we did. Her clinical bottom line: patients coming off Wegovy injections can reasonably transition to Foundayo. Patients on tirzepatide (Zepbound or Mounjaro) should stay on tirzepatide.
The reason is structural. Zepbound is a dual-receptor agonist, working on both GIP and GLP-1 pathways. Foundayo works on GLP-1 alone. You cannot replicate dual-receptor potency with a single-receptor pill. This lines up with SURMOUNT-5, the head-to-head trial published in the New England Journal of Medicine, where Zepbound produced 20.2% weight loss to Wegovy’s 13.7%.
If you are succeeding on Zepbound, stay on Zepbound. The math is clear.
What Makes Foundayo Different
Here is the chemistry, in plain English: Wegovy and Zepbound are peptides. Fragile chains of amino acids that your stomach will shred before they can do any work. That is why they are injections. It is also why oral Wegovy (the current pill version of semaglutide) requires an empty stomach, a specific water amount, and a 30-minute wait before you can eat or drink anything else. The peptide has to be gently escorted past your stomach acid.
Foundayo is a different beast. It is a small-molecule drug. Engineered from the ground up to survive your digestive tract intact. That is why you can take it whenever you want. With food. Without. Morning or night. No timing rules.
For patients who have been hesitant to start a GLP-1 because of the needle, the weekly ritual, or the logistical hassle, this is not a minor upgrade. It is the first version of this drug class that fits cleanly into a normal daily routine. Think about the dominance of the birth-control pill and why it won market dominance over competitors: “The Pill” wins on autonomy and routine. It is a low-friction habit that feels like a vitamin, not a medical procedure. No office visit. No needle. For many patients, that psychological comfort is worth trading a few percentage points of perfect-use efficacy.
Foundayo Switch Calculator
Thinking about switching from your weekly injection to the new Foundayo pill? See what the clinical trial data says to expect, based on your situation.
Step 1
What medication are you currently on?
Step 2
How much weight have you lost so far?
Your projection
Based on ATTAIN-MAINTAIN trial data, here is what a switch to Foundayo would likely look like for someone in your situation.
Weight you’ve lost
—
with your current injection
Projected regain on pill
—
over 12 months after switching
The pill may be right for some patients, but the clinical picture is personal. Talk with a Rivas provider about whether switching is the right move for you.
Book a Consultation →Projections are based on the ATTAIN-MAINTAIN Phase 3 clinical trial (Eli Lilly, December 2025), which measured the average percentage of lost weight regained when patients switched from injectable GLP-1 medications to Foundayo over 52 weeks. Individual results vary. This tool is for educational purposes and does not constitute medical advice. Decisions about changing medications should be made in consultation with a qualified healthcare provider.
Who Foundayo Is Actually Right For
Foundayo is a useful addition to the treatment menu. It is just not the right tool for every patient. In our clinical experience, and in line with Dr. Tchang’s framework, there are four types of patients who are strong candidates.
- Patients who will not inject. For them, the choice is not Foundayo versus Zepbound. It is Foundayo versus the Wegovy Pill.
- Patients on other timing-sensitive oral medications. This is a nuance most patients never think about. Levothyroxine (thyroid), alendronate (osteoporosis), and proton pump inhibitors (reflux) all require empty-stomach dosing with a 30-minute wait. So does oral Wegovy. Foundayo does not. For a patient already juggling a strict morning-medication routine, this is a real friction point solved.
- Patients with needle fatigue after long-term use. Obesity is a chronic disease. Treatment is typically lifelong. Patients who have succeeded on Wegovy injections and want a more convenient maintenance option have a data-supported path to Foundayo. ATTAIN-MAINTAIN confirms the switch works for this group specifically.
- Patients who need moderate weight loss (roughly 10%). Not everyone needs to lose 20% of their body weight. A patient 25 to 30 pounds over their goal, with prediabetes or joint pain, may not need Zepbound’s maximum potency. Foundayo delivered 5.1% to 11.1% average weight loss in clinical trials depending on dose. That’s enough to resolve comorbidities for many patients.
Not sure if Foundayo is right for you?
Your provider evaluates your history and goals at your first visit, and can start treatment the same day.
Book a Visit →How Foundayo Is Dosed
Foundayo is a once-daily tablet with a conservative, six-step dose escalation designed to minimize the GI side effects that come with every GLP-1.
- Starting dose: 0.8 mg
- Month 2: 2.5 mg
- Month 3: 5.5 mg (lowest therapeutic dose)
- Month 4: 9 mg
- Month 5: 14.5 mg
- Maximum: 17.2 mg
At the 17.2 mg maximum, about 1 in 2 patients lost 10% or more of their body weight over a year in clinical trials.
Appetite suppression kicks in within 4 to 8 hours of the first tablet, with full effect reached after about a week of consistent daily dosing. That is notably faster onset than patients experience with weekly injectables.
What It Costs
Eli Lilly has structured self-pay pricing by dose tier, paid directly to Lilly.
Dose increases are based on individual response and tolerability. Many patients hold at 5.5 or 9 mg.
A note on consistency: if you let your prescription lapse more than 45 days, the top-dose pricing jumps to $349/month. Staying on your schedule is not just good medicine, it is also good math. For a full breakdown of what GLP-1 treatment costs at our practice, see our pricing page.
The Bigger Problem: Who Is Actually Running Your Treatment
There is a larger issue behind the Foundayo launch that most patients will not see until it affects them.
GLP-1 therapy is now available through more channels than any medication in recent memory. Primary care. Specialist clinics. Manufacturer direct-pay programs. Digital health platforms. Retail providers. Online-only telehealth services. Each pathway has different pricing, different levels of clinical oversight, and different degrees of responsibility for your long-term outcome.
On the surface, this looks like progress. Barriers are lower. Access is up. But access expanding rapidly without coordination creates a different problem: fragmented care.
In a chronic disease like obesity, fragmentation has real consequences. Continuity gets harder. Accountability gets blurred. Adherence, the biggest predictor of long-term success, becomes fragile when patients are switching providers and platforms every few months based on whoever is cheapest that week.
This is exactly why the Foundayo launch matters beyond the molecule. Online-only platforms will aggressively market Foundayo as a substitute for Zepbound because the margins are better and the compliance lift is lower. Patients who are succeeding on a weekly Zepbound injection, with a clinician who knows their history, will be offered a pill with no clinical reason to switch and no provider continuity on the other side.
If you take nothing else from this piece, take this: whoever writes your GLP-1 prescription should also be the person answering your call when something is not working. That is the difference between a treatment plan and a transaction.
How We Think About It at Rivas
We have been treating obesity as a chronic disease for more than 34 years. The one thing we have learned is that the question is almost never “what is the best weight loss medication.” The question is always “what is the best weight loss medication for this patient, at this point in their treatment.”
From Our Chief Physician Assistant
I tell tirzepatide patients the same thing every time: the pill is a real medication, and for the right patient it’s a great option. But if you’re already succeeding on your current injection, you’re not the right patient for a switch. You’ve worked hard for your results, and a switch is likely to result in some weight regain.
Clinical opinions reflect individual provider experience. Individual results vary.
With Foundayo now on the menu, the decisions we walk through with every patient include:
- What is your current trajectory, if you are on treatment?
- What are your goals, modest or substantial?
- Any contraindications or drug interactions that rule options out?
- What is your budget for sustained, long-term treatment?
- Have you tried injectable GLP-1s, and how did you respond?
- Are there real adherence barriers, travel, needle aversion, logistics, other oral medications, that favor the pill?
- If you are on Zepbound and succeeding, is there a non-convenience reason to consider changing?
These questions are why weekly in-person visits with a named provider matter. The GLP-1 landscape is moving faster than most online prescribing platforms can keep up with. An algorithm that matches you to a medication based on a 5-minute intake form is not going to catch the nuance that ATTAIN-MAINTAIN just added to every switching decision.
The Bottom Line
Foundayo is good news. It expands the menu. It removes real barriers for patients who have been hesitant to start. It brings more competition into a class of medications where patients have been asking for more choices. It is not, however, a universal upgrade. The right answer depends on you. Not on a headline. Not on a YouTube video. Not on a social post. On a conversation with a provider who knows your history and will still be your provider next year.
Related Links:
- Stopping your GLP-1? Here’s the exercise math you need now
- Have you hit a Wegovy or Ozempic plateau? Here’s what’s happening
- Reached your goal on Wegovy? Here’s what maintenance looks like
Frequently Asked Questions
For most patients currently succeeding on Zepbound, the answer is no. The ATTAIN-MAINTAIN trial showed patients who switched from Zepbound to Foundayo regained approximately 20% of their lost weight over 52 weeks, roughly 11 pounds on average. Zepbound is a dual-receptor agonist; Foundayo targets only GLP-1. The single-receptor pill cannot replicate the dual-receptor injection’s maintenance potency. If you are tolerating Zepbound well and losing weight, the clinical data supports staying on it.
Yes, with much less risk. ATTAIN-MAINTAIN showed Wegovy patients regained only about 5% of their lost weight (roughly 2 pounds) when they switched to Foundayo. For Wegovy users who want a more convenient maintenance option, the switch is a reasonable clinical choice. Discuss it with your Rivas provider at your next visit.
No. In clinical trials, Foundayo produced an average weight loss of 11.2% to 12.4% over 72 weeks in non-diabetic patients with obesity. Zepbound produced 20.2% in the head-to-head SURMOUNT-5 trial. Foundayo is closer to Wegovy (13.7% in SURMOUNT-5) than to Zepbound for total weight loss. For patients who need maximum weight loss, Zepbound remains the most effective option available.
Post-approval safety requirements are standard practice. The FDA approves medications when the benefit-risk profile is clear, then requires manufacturers to keep building the evidence base in real-world use. The additional requirements for Foundayo (cardiovascular outcomes, liver effects, delayed gastric emptying, use in lactating women) are not a red flag. They are the system working as designed.
Foundayo has a GI side effect profile similar to other GLP-1 medications. In clinical trials, nausea occurred in 26% to 35% of patients, constipation in 20% to 27%, diarrhea in 21% to 25%, and vomiting in 13% to 24%. Discontinuation rates from GI side effects were under 10%. Foundayo also carries a boxed warning for thyroid C-cell tumors, identical to other GLP-1s. Patients with a personal or family history of medullary thyroid carcinoma or MEN 2 should not take this medication.
Patients of childbearing potential should use a barrier form of contraception for 30 days after starting Foundayo, and 30 days after any dose change. The drug can reduce the effectiveness of oral contraceptives during escalation.
Patients planning to conceive should discontinue at least 10 days before planned conception. Foundayo has a half-life of 29 to 49 hours.
Patients with severe liver disease (Child-Pugh class C) should not take Foundayo. It is metabolized primarily through the liver via CYP3A4.
Patients on simvastatin should cap at 20 mg daily. Atorvastatin up to 40 mg and rosuvastatin up to 20 mg are fine.
Patients on CYP3A4-interacting medications (clarithromycin, carbamazepine, and others) need plasma-level oversight. Disclose every prescription you are on.
Eli Lilly has tiered self-pay pricing: $149/month at the starting doses (0.8 mg, 2.5 mg), $199/month at the mid-range doses (5.5 mg, 9 mg), and $299/month at the top doses (14.5 mg, 17.2 mg). If your prescription lapses more than 45 days, top-dose pricing jumps to $349/month. See our pricing page for a full breakdown of GLP-1 treatment costs at Rivas.
Most medications are compatible with Foundayo, but a few require caution. Patients on simvastatin should cap at 20 mg daily. Strong CYP3A4 inhibitors (clarithromycin) or inducers (carbamazepine) can significantly change Foundayo plasma levels. Oral contraceptives may be less effective during dose escalation, so barrier contraception is recommended for 30 days after start and after any dose change. Disclose every prescription and over-the-counter medication to your provider before starting.
